BioLife Solutions, Inc. (NASDAQ:BLFS) Shares Bought by D.A. Davidson & CO.

D.A. Davidson & CO. raised its holdings in BioLife Solutions, Inc. (NASDAQ:BLFS) by 1.3% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 41,179 shares of the medical equipment provider’s stock after acquiring an additional 519 shares during the quarter. D.A. Davidson & CO.’s holdings in BioLife Solutions were worth $1,069,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of BLFS. Mark Sheptoff Financial Planning LLC acquired a new stake in shares of BioLife Solutions in the third quarter valued at $28,000. Quest Partners LLC purchased a new stake in BioLife Solutions during the 3rd quarter worth about $57,000. Summit Global Investments acquired a new stake in BioLife Solutions in the 3rd quarter valued at about $228,000. Intech Investment Management LLC purchased a new position in shares of BioLife Solutions in the 3rd quarter valued at about $255,000. Finally, Stifel Financial Corp grew its position in shares of BioLife Solutions by 5.4% during the third quarter. Stifel Financial Corp now owns 12,988 shares of the medical equipment provider’s stock worth $325,000 after buying an additional 670 shares in the last quarter. Institutional investors and hedge funds own 93.24% of the company’s stock.

Insider Buying and Selling at BioLife Solutions

In related news, EVP Aby J. Mathew sold 7,604 shares of the company’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $27.33, for a total value of $207,817.32. Following the completion of the sale, the executive vice president now directly owns 276,315 shares of the company’s stock, valued at $7,551,688.95. This represents a 2.68 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Troy Wichterman sold 987 shares of the firm’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $27.02, for a total value of $26,668.74. Following the transaction, the chief financial officer now owns 121,779 shares in the company, valued at $3,290,468.58. This represents a 0.80 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 11,678 shares of company stock worth $317,990 over the last 90 days. Corporate insiders own 2.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the stock. TD Cowen raised their target price on shares of BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. KeyCorp increased their price objective on shares of BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a research report on Friday, December 13th. HC Wainwright decreased their price objective on shares of BioLife Solutions from $29.00 to $27.00 and set a “buy” rating for the company in a research report on Monday, November 18th. Benchmark reissued a “buy” rating and issued a $30.00 target price on shares of BioLife Solutions in a report on Thursday, December 19th. Finally, Northland Securities raised their price target on BioLife Solutions from $28.00 to $31.00 and gave the company an “outperform” rating in a research note on Wednesday, January 8th. One analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $29.43.

BioLife Solutions Trading Down 3.1 %

NASDAQ BLFS opened at $26.67 on Monday. The firm’s fifty day moving average price is $26.93 and its 200 day moving average price is $25.51. BioLife Solutions, Inc. has a 12 month low of $14.50 and a 12 month high of $29.55. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.78 and a quick ratio of 1.78. The company has a market capitalization of $1.24 billion, a price-to-earnings ratio of -25.16 and a beta of 1.91.

BioLife Solutions Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.